Position in RDY
as of Mar 31, 2026
· filed Apr 29, 2026
Position Value
$1,005,288
+$152,667 QoQ
Shares Held
72,584
+19.5% QoQ
Ownership
0.009%
of shares outstanding
% of Portfolio
0.04%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Dec 2024
6 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in RDY Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - Specialty & Generic
Healthcare · as of Mar 31, 2026Brooklyn Investment Group holds $16,769,575 across 17 Drug Manufacturers - Specialty & Generic names. RDY ranks #6 (6.0% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | TAK |
Takeda Pharmaceutical Co Ltd
|
174,896 | $3,239,073 | |
| 2 | HLN |
Haleon plc
|
260,541 | $2,608,015 | |
| 3 | UTHR |
UNITED THERAPEUTICS Corp
|
3,728 | $2,210,629 | |
| 4 | ZTS |
Zoetis Inc.
|
14,892 | $1,760,383 | |
| 5 | TEVA |
Teva Pharmaceutical Industries Ltd
|
56,904 | $1,713,948 | |
| 6 | RDY |
Dr Reddys Laboratories Ltd
This page
|
72,584 | $1,005,288 | |
| 7 | NBIX |
Neurocrine Biosciences Inc
|
4,947 | $651,717 | |
| 8 | ELAN |
Elanco Animal Health Inc
|
25,358 | $606,816 |
All Filings in RDY
Export CSV
6 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $1,005,288 | 72,584 | Shares | Defined | 2026-04-29 | |
| 2025-12-31 | $852,621 | 60,728 | Shares | Defined | 2026-02-12 | |
| 2025-09-30 | $257,861 | 18,445 | Shares | Defined | 2025-11-14 | |
| 2025-06-30 | $289,387 | 19,254 | Shares | Defined | 2025-08-14 | |
| 2025-03-31 | $84,323 | 6,393 | Shares | Defined | 2025-05-13 | |
| 2024-12-31 | $17,053 | 1,080 | Shares | Defined | 2025-01-15 | |
| No filing history on record for this holder in this stock. | ||||||